Efficacy of Ustekinumab on Skin Reactions Induced by Tumor Necrosis Factor-Alpha Inhibitors in Patients with Inflammatory Bowel Disease
Inflammatory Intestinal Diseases · 09.07.2026 · 11 (1) · 260-269
DOI: 10.1159/000552245 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Intestinal Diseases, online erschienen am 09.07.2026. Verfasst von Koji Fujimoto und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Tumor necrosis factor-alpha (TNF-α) inhibitors sometimes induce skin reactions in patients with Crohn’s disease (CD) and ulcerative colitis (UC). Ustekinumab (UST) has been reported to be effective in treating TNF-α inhibitor-induced skin reactions. Here, we aimed to investigate the efficacy of UST on skin reactions and its long-term efficacy in the treatment of CD and UC.
Methods
CD and UC patients who switched to UST due to skin reactions (skin reaction group) or secondary failure of TNF-α inhibitors (non-skin reaction group) in our hospital between June 2017 and September 2023 were included. The primary outcome was the efficacy of UST for skin reactions, classified as complete remission, partial remission, or no response. The secondary outcome was cumulative UST continuation, assessed using Kaplan-Meier analysis and Cox proportional hazards models. Inverse probability of treatment weighting (IPTW) was performed after adjusting for age, clinical remission status, and type of inflammatory bowel disease (CD or UC).
Results
Eighty-two patients (CD, 68; UC, 14) were included; 20 developed skin reactions, most commonly psoriasiform dermatitis (30%). After switching to UST, 15 patients achieved complete remission of the skin reaction, and four achieved partial remission. After IPTW adjustment, the UST continuation rate did not differ significantly between groups (p = 0.205), and skin reactions were not associated with UST continuation (hazard ratio 0.55; 95% CI: 0.24–1.26; p = 0.159).
Conclusions
UST was effective for 95% of TNF-α inhibitor-induced skin reactions without affecting long-term UST continuation, supporting its clinical utility.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Zitieren
APA
Fujimoto, K., Hosomi, S., Kobayashi, Y., Nakata, R., Nishida, Y., Maruyama, H., Ominami, M., Nadatani, Y., Fukunaga, S., Otani, K., Tanaka, F., & Fujiwara, Y. (2026). Efficacy of Ustekinumab on Skin Reactions Induced by Tumor Necrosis Factor-Alpha Inhibitors in Patients with Inflammatory Bowel Disease. Inflammatory Intestinal Diseases, 11(1), 260-269. https://doi.org/10.1159/000552245
Vancouver
Fujimoto K, Hosomi S, Kobayashi Y, Nakata R, Nishida Y, Maruyama H, et al. Efficacy of Ustekinumab on Skin Reactions Induced by Tumor Necrosis Factor-Alpha Inhibitors in Patients with Inflammatory Bowel Disease. Inflammatory Intestinal Diseases. 2026;11(1):260-269. doi:10.1159/000552245
BibTeX
@article{Fujimoto2026,
author = {Fujimoto, Koji and Hosomi, Shuhei and Kobayashi, Yumie and Nakata, Rieko and Nishida, Yu and Maruyama, Hirotsugu and Ominami, Masaki and Nadatani, Yuji and Fukunaga, Shusei and Otani, Koji and Tanaka, Fumio and Fujiwara, Yasuhiro},
title = {Efficacy of Ustekinumab on Skin Reactions Induced by Tumor Necrosis Factor-Alpha Inhibitors in Patients with Inflammatory Bowel Disease},
journal = {Inflammatory Intestinal Diseases},
year = {2026},
volume = {11},
number = {1},
pages = {260--269},
doi = {10.1159/000552245}
}
EUVIMED